Findings of this current work prompted that Sal A maybe a promising drug and TAGLN2/PI3K/Akt pathway might serve as therapeutic targets, which are able to become prospective adjuvant in glioma chemotherapy clinically. This evidence concerns the gene TAGLN2 and central nervous system cancer.